Biotech

All Articles

Kairos goes social with $6M IPO to cash tests of cancer cells drug

.Along with a trio of biotechs reaching the Nasdaq on Friday, it was actually quick and easy to miss...

Vaccine as well as Keytruda combo reliable in squamous tissue cancer

.Immune system gate preventions are the superheroes of cancer cells therapy. Medicines like Bristol ...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings as ...

Regeneron's Opdualag rival reveals 57% action fee

.Regeneron is back along with long-term follow-up for its own LAG-3 prevention as well as PD-1 inhib...

AstraZeneca blog posts information on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early check out the performance of its own internal antibody-drug con...

iTeos- GSK's TIGIT superstar shows purposeful renovation

.After declaring a period 3 launch based on beneficial midstage end results, iTeos and GSK are lastl...

More joint FDA may accelerate rare health condition R&ampD: document

.The FDA needs to be actually a lot more available as well as collaborative to let loose a rise in a...

Zenas, MBX, Bicara scalp to Nasdaq in scorching time for biotech IPOs

.It's an uncommonly busy Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as Bicara ...

Atea's COVID antiviral falls short to halt hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has actually neglected yet another COVID-19 trial, yet the biotech ...

Neurocrine's proposal to conserve mental illness prospect falls short

.Neurocrine Biosciences' schizophrenia system pivot has actually stopped working. The biotech was ac...